Q-omics provides the consensus-scored TMEM65 profile across patient tissues and cancer cell-line models. TMEM65 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM65 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TMEM65 protein abundance shows 19,391 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where TMEM65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM65 survival associations across molecular data types. TMEM65 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM65 RNA expression–survival associations across cancer types. High TMEM65 expression shows unfavorable associations in UVM, BRCA, KIRP, LIHC and CESC, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM65 RNA expression.
This table summarizes TMEM65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM65 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, STAD and LUSC. The HNSC box plot shows higher TMEM65 RNA expression in tumor versus normal tissue (log2 FC = +0.889, t-test p < 0.001).
This table shows molecular features associated with TMEM65 in patient tissues and cancer cell lines. In patient samples, TMEM65 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM65 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
